Dear Editor
The p53 paralog TPp73 gene gives rise to a variety of functionally distinct polypeptides involved in the control of growth arrest, apoptosis and differentiation. Multiple TA (transactivation competent, pro-apoptotic and anti-proliferative) p73 carboxy-terminal splicing isoforms (α, β, γ, δ, ɛ, ζ, η and η1) are expressed from the P1p73 promoter (reviewed by Giombini et al1 and references therein). A second intragenic promoter, P2p73, controls the expression of dominant-negative (ΔN) variants that lack the amino-terminal transactivation domain and act as dominant-negative repressors of p53- and p73-dependent apoptosis (reviewed by Giombini et al1 and references therein). Changes in TAp73 and ΔN-p73 expression rather than inactivating mutations within the TP73 gene, have been described in many human tumors.2 Unlike acute lymphoid leukemias, which mainly display promoter CpG islands hypermethylation, acute myeloid leukemia is characterized by a relative enrichment of shorter TAp73 isoforms, and in the case of acute promyelocytic leukemia (APL), a peculiar lack of ΔN-p73 expression has been reported by our group.3, 4, 5
In this study, we have investigated the molecular mechanisms underlying the transcriptional repression of the P2p73 promoter that leads to the severe reduction of ΔN-p73 expression in APL blasts. We identified the promyelocytic leukemia (PML)/RARα fusion protein as a direct regulator of the P2p73 transcriptional activity and showed that retinoic acid (RA) treatment relieves P2p73 repression in vitro and restores ΔN-p73 expression in APL patients in vivo. Notably, we found that ΔN-p73 expression acts as a pro-differentiation factor in APL cells.
Sequence analysis and binding-site scanning of the P2p73 promoter reveals, in addition to the well-characterized p53 and AP1 sites, the presence of five conserved putative RA-responsive element (RARE) sites (positions −5242 −5209; −4413 −4372; −3843 −3826; −3081 −3043; −2871 −2824) and several RARE half-sites (Figure 1a). By generating deletion mutants of the P2p73 promoter, we found that deletion of a large genomic fragment containing either the putative RARE elements (P2-2500) or several RARE half sites (P2-1500) results in an increase of the basal transcriptional activity of the P2p73 promoter (Figure 1b, left panel). The transcriptional activity of the P2–55 promoter deletion mutant returns to levels comparable to those of the full-length P2–5800 promoter, thus suggesting the presence of positive regulatory elements between positions –5800 and –1500 (Figure 1b, left panel). To analyze the transcriptional effects of the PML/RARα fusion protein on the P2p73 promoter, we performed transactivation assays using the deletion mutants described above (Figure 1a). We found that exogenously expressed PML/RARα severely downregulates the P2–5800, P2–2500 and P2–1500 promoter constructs, whereas it has no effect on the P2–55 promoter mutant (Figure 1b, right panel). By using crosslinked chromatin derived either from PR9 cells, a U937-derived cell line in which exogenous PML/RARα expression is Zinc-inducible, or from NB4 promyelocytic leukemia cells, we found that PML/RARα is recruited in vivo onto multiple sites in the P2p73 promoter (Figure 1a, right panel; Figure 1c). Altogether, these findings indicate that PML/RARα fusion protein binds to and inhibits the transcriptional activity of the P2p73 promoter.
Several in vitro and in vivo studies have shown that RA treatment blocks PML/RARα activity either by inducing changes in the composition of chromatin-bound PML/RARα complexes or by directing PML/RARα to degradation, thus relieving its repressive effects on RA target genes transcription.6 Indeed, we found that RA treatment of PR9 cells determined a significant reduction of the PML/RARα fusion protein bound to the P2p73 promoter (Figure 1c, upper panel; Supplementary Figure 1). A similar pattern of PML in vivo binding to the ΔN-p73 promoter was also found in NB4 cells (Figure 1c, lower panel). It has been shown previously that the binding of PML/RARα to the promoter of its transcriptional target gene RARβ2 is not affected upon RA treatment.7 The switch from repression to transcriptional activation has been related to the substitution of HDAC1-containing complexes with transcriptionally active PML/RARα-p300 protein complexes.7 Although we cannot exclude that the small amount of PML/RARα still bound to P2p73 promoter (Figure 1c) may be engaged in transcriptionally active complexes, our results strongly suggest that the actual amount of PML/RARα recruited in vivo is critical for the transcriptional repression of the P2p73 promoter. Our findings could also be explained by the existence of different subsets of PML/RARα target genes whose transcriptional control is exerted through distinct molecular mechanisms. Furthermore, transactivation assays confirmed that the inhibitory effect of PML/RARα on the P2p73 promoter is reversed in the presence of RA (Figure 1d). Conversely, Zinc-inducible expression of PML/RARα in PR9 cells (Figure 1e, left panel) leads to a decrease of ΔN-p73 transcripts (Figure 1e, right panel), whereas RA treatment strongly induces ΔN-p73 mRNA expression (Figure 1e, right panel). We next investigated the impact of exogenously expressed ΔN-p73 on NB4 cells survival and differentiation. We found that ΔN-p73-expressing cells acquire the membrane differentiation markers CD11b, CD11c and CD15 in the absence of RA exposure (Figure 1f, right panel; Supplementary Figure 2) and respond to RA both with rapid (i.e. after 24 hours), morphological changes (i.e., size reduction, decreased nucleo/cytoplasmic ratio and more condensed chromatin) (Figure 1f, left panel) and with higher levels of CD11b, CD11c, CD15 and CD54 antigens expression (Figure 1f, right panel; Supplementary Figure 2). In contrast to these marked effects on cell differentiation, ΔN-p73 expression did not modify NB4 cells proliferation and survival (data not shown).
Finally, to further evaluate whether RA-mediated release of ΔN-p73 expression from PML/RARα transcriptional repression is recapitulated in APL patients, we analyzed ΔN-p73 mRNA expression in blasts from 22 APL patients before and after conventional RA treatment. In agreement with our previous observation,4 we found that ΔN-p73 expression is very low in pre-treatment samples and it is strongly increased in 18 out of 22 patients (81.8%) after therapy (Supplementary Figure 3).
Altogether, our findings show that ΔN-p73 is a transcriptional target of the PML/RARα oncogene. This results in the transcriptional repression of ΔN-p73 providing one potential molecular basis underlying the lack of ΔN-p73 expression in a large subset of APL leukemias. The role of PML/RARα in ΔN-p73 repression is confirmed by the ability of RA to restore its expression both in vitro and in vivo. The observation that ΔN-p73 expression induces a number of differentiation markers in APL cells and cooperates with RA-induced differentiation in vitro suggests that ΔN-p73 might be necessary for proper myeloid differentiation. Indeed, ΔN-p73 expression is modulated during muscle and kidney differentiation.8, 9 Although ΔN-p73 has been mainly involved in the inhibition of p53-, TAp63- and TAp73-dependent transcription of target gene promoters containing p53REs, a series of recent evidences indicates that ΔN-p73 may directly and indirectly activate transcription from a number of target genes.10 Thus, the ability of RA to remove the differentiation block of APL leukemias and to restore ΔN-p73 expression might result in the activation of a specific subset of yet unidentified genes involved in myeloid differentiation.
References
Giombini E et al. Gene Ther Mol Biol 2005; 9: 377–392.
Grob TJ et al. Cell Death Differ 2001; 8: 1213–1223.
Kawano S et al. Blood 1999; 94: 1113–1120.
Rizzo MG et al. Leukemia 2004; 18: 1804–1809.
Tschan MP et al. Biochem Biophys Res Commun 2000; 277: 62–65.
Jing Y . Leuk Lymphoma 2004; 45: 639–648.
DiCroce L et al. Science 2002; 295: 1079–1082.
Belloni L et al. Oncogene 2006; 25: 3606–3612.
Saifudeen Z et al. J Biol Chem 2005; 280: 23094–23102.
Lanza M et al. Cell Cycle 2006; 5: 1996–2004.
Acknowledgements
This work was supported by Associazione Italiana per la Ricerca sul Cancro (AIRC), Ministero della Salute-Italy and European Community (Eu Active p53 Consortium). This publication reflects the authors' views and not necessarily those of the European Community.
Author information
Authors and Affiliations
Corresponding authors
Additional information
Supplementary Information accompanies the paper on Cell Death and Differentiation website (http://www.nature.com/cdd)
Rights and permissions
About this article
Cite this article
Mainardi, S., Pelosi, A., Palescandolo, E. et al. ΔN-p73 is a transcriptional target of the PML/RARα oncogene in myeloid differentiation. Cell Death Differ 14, 1968–1971 (2007). https://doi.org/10.1038/sj.cdd.4402210
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.cdd.4402210
This article is cited by
-
miRNA let-7c promotes granulocytic differentiation in acute myeloid leukemia
Oncogene (2013)
-
Role of the promyelocytic leukaemia protein in cell death regulation
Cell Death & Disease (2012)
-
A restricted signature of miRNAs distinguishes APL blasts from normal promyelocytes
Oncogene (2009)